Neuromyelitis optika und Susac-Syndrom

Zusammenfassung

Der Ausschluss von Differenzialdiagnosen ist elementarer Bestandteil der zeitgemäßen Diagnosestellung der Multiplen Sklerose (MS). Zwei seltene, aufgrund unterschiedlicher Therapiestrategien und Prognosen aber wichtige Differenzialdiagnosen der MS sind die Neuromyelitis optika und das Susac-Syndrom. Während erstere in den letzten Jahren zunehmend als eigenständige Erkrankung, denn als Variante der MS angesehen wird, wird letzteres in vielen Fällen gar nicht erst erkannt. In dieser Übersicht werden beide Erkrankungen vorgestellt, wobei der Schwerpunkt auf der differenzialdiagnostischen Abgrenzung von der MS liegt.

Schlüsselwörter

Multiple Sklerose - Neuromyelitis optika - Susac-Syndrom - Differenzialdiagnose

• Literatur

• 1 Compston A, Coles A. Multiple sclerosis. Lancet 2008; 372 9648 1502-17.
• 2 McDonald WI. et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50 (01) 121-7.
• 3 Polman CH. et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005; 58 (06) 840-6.
• 4 Wingerchuk DM. et al. The spectrum of neuromyelitis optica. Lancet Neurol 2007; 06 (09) 805-15.
• 5 Weinshenker BG. et al. OSMS is NMO, but not MS: proven clinically and pathologically. Lancet Neurol 2006; 05 (02) 110-1.
• 6 Lucchinetti C. et al. A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125 (07) 1450-1.
• 7 Lennon VA. et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364 9451 2106-12.
• 8 Lennon VA. et al. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202 (04) 473-7.
• 9 Paul F. et al. Antibody to aquaporin 4 in the diagnosis of neuromyelitis optica. PLoS Med 2007; 04 (04) e133.
• 10 Jarius S. et al. NMO-IgG in the diagnosis of neuromyelitis optica. Neurology 2007; 68 (13) 1076-7.
• 11 Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 06 (07) 383-92.
• 12 Graber DJ, Levy M, Kerr D, Wade WF. Neuromyelitis optica pathogenesis and aquaporin 4. J Neuroinflammation 2008; 05: 22.
• 13 Wingerchuk DM. et al. The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 1999; 53 (05) 1107-14.
• 14 Poppe AY. et al. Neuromyelitis optica with hypothalamic involvement. Mult Scler 2005; 11 (05) 617-21.
• 15 Magaña SM. et al. Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders. Neurology 2009; 72 (08) 712-7.
• 16 Wingerchuk DM. et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66 (10) 1485-9.
• 17 Pittock SJ. et al. Brain abnormalities in neuromyelitis optica. Arch Neurol 2006; 63 (03) 390-6.
• 18 Sellner J. et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol 2010; 17 (08) 1019-32.
• 19 de Seze J. et al. Is Devic’s neuromyelitis optica a separate disease? A comparative study with multiple sclerosis. Mult Scler 2003; 09 (05) 521-5.
• 20 McLean BN, Luxton RW, Thompson EJ. A study of immunoglobulin G in the cerebrospinal fluid of 1007 patients with suspected neurological disease using isoelectric focusing and the Log IgG-Index. A comparison and diagnostic applications. Brain 1990; 113 (05) 1269-89.
• 21 Waters P. et al. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 2008; 65 (07) 913-9.
• 22 Jarius S. et al. Standardized method for the detection of antibodies to aquaporin-4 based on a highly sensitive immunofluorescence assay employing recombinant target antigen. J Neurol Sci 2010; 291 (1–2) 52-6.
• 23 Kalluri SR. et al. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch Neurol 2010; 67 (10) 1201-8.
• 24 Wingerchuk DM, Weinshenker BG. Neuromyelitis optica: Clinical predictors of a relapsing course and survival. Neurology 2003; 60 (05) 848-53.
• 25 Watanabe S. et al. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult Scler 2007; 13 (01) 128-32.
• 26 Cree BAC. et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64 (07) 1270-2.
• 27 Trebst C. [Diagnosis and treatment of neuromyelitis optica: Consensus recommendations of the Neuromyelitis Optica Study Group.]. Nervenarzt. 2010 Dez 22 www.ncbi.nlm.nih.gov/pubmed/21174070
• 28 Bot JCJ. et al. Spinal cord abnormalities in recently diagnosed MS patients: added value of spinal MRI examination. Neurology 2004; 62 (02) 226-33.
• 29 Weinshenker BG. et al. Neuromyelitis optica IgG predicts relapse after longitudinally extensive transverse myelitis. Ann Neurol 2006; 59 (03) 566-9.
• 30 Jarius S. et al. Polyspecific, antiviral immune response distinguishes multiple sclerosis and neuromyelitis optica. J Neurol Neurosurg Psychiatr 2008; 79 (10) 1134-6.
• 31 Susac JO, Hardman JM, Selhorst JB. Microangiopathy of the brain and retina. Neurology 1979; 29 (03) 313-6.
• 32 Eluvathingal TJMuttikkal, Vattoth S, Keluth VNChavan. Susac syndrome in a young child. Pediatr Radiol 2007; 37 (07) 710-3.
• 33 McLeod DS. et al. Retinal and optic nerve head pathology in Susac’s Syndrome. Ophthalmology. 2010 Okt 2 www.ncbi.nlm.nih.gov/pubmed/20920828
• 34 O’Halloran HS. et al. Microangiopathy of the brain, retina, and cochlea (Susac syndrome). A report of five cases and a review of the literature. Ophthalmology 1998; 105 (06) 1038-44.
• 35 Petty GW. et al. Retinocochleocerebral vasculopathy. Medicine (Baltimore) 1998; 77 (01) 12-40.
• 36 Heiskala H. et al. Microangiopathy with encephalopathy, hearing loss and retinal arteriolar occlusions: two new cases. J Neurol Sci 1988; 86 (2–3) 239-50.
• 37 Barker R. et al. Microangiopathy of the brain and retina with hearing loss in a 50 year old woman: extending the spectrum of Susac’s syndrome. J Neurol Neurosurg Psychiatr 1999; 66 (05) 641-3.
• 38 Ballard E, Butzer JF, Donders J. Susac’s syndrome: neuropsychological characteristics in a young man. Neurology 1996; 47 (01) 266-8.
• 39 Bogousslavsky J. et al. Encephalopathy, deafness and blindness in young women: a distinct retinocochleocerebral arteriolopathy?. J Neurol Neurosurg Psychiatry 1989; 52 (01) 43-6.
• 40 MacFadyen DJ, Schneider RJ, Chisholm IA. A syndrome of brain, inner ear and retinal microangiopathy. Can J Neurol Sci 1987; 14 (03) 315-8.
• 41 Monteiro ML. et al. A microangiopathic syndrome of encephalopathy, hearing loss, and retinal arteriolar occlusions. Neurology 1985; 35 (08) 1113-21.
• 42 Papeix C. et al. [Susac’s syndrome: improvement with combined cyclophosphamide and intravenous immunoglobulin therapy]. Rev Neurol (Paris) 2000; 156 (8–9) 783-5.
• 43 Susac JO. Susac’s syndrome: the triad of microangiopathy of the brain and retina with hearing loss in young women. Neurology 1994; 44 (04) 591-3.
• 44 Tashima K. et al. Susac’s syndrome: beneficial effects of corticosteroid therapy in a Japanese case. Intern Med 2001; 40 (02) 135-9.
• 45 Magro C. Susac’s syndrome: an autoimmune endotheliopathy. Abstract presented at 1st Susac’s Syndrome Symposium, held at Ohio State University, Columbus. 2005
• 46 Susac JO, Egan RA, Rennebohm RM, Lubow M. Susac’s syndrome: 1975–2005 microangiopathy/ autoimmune endotheliopathy. J Neurol Sci 2007; 257 (1–2) 270-2.
• 47 Waldman J, Knight D. Antiendothelial cell antibodies in Susac’s syndrome. Abstract presented at the 1st Susac’s Syndrome Symposium, held at Ohio State University, Columbus. 2005
• 48 Jarius S. et al. Anti-endothelial serum antibodies in a patient with Susac’s syndrome. J Neurol Sci 2009; 285 (1–2) 259-61.
• 49 Aubart-Cohen F. et al. Long-term outcome in Susac syndrome. Medicine (Baltimore) 2007; 86 (02) 93-102.
• 50 Petty GW. et al. Recurrence of Susac syndrome (retinocochleocerebral vasculopathy) after remission of 18 years. Mayo Clin Proc 2001; 76 (09) 958-60.
• 51 Dörr J. et al. Encephalopathy, visual disturbance and hearing loss-recognizing the symptoms of Susac syndrome. Nat Rev Neurol 2009; 05 (12) 683-8.
• 52 Susac JO. et al. MRI findings in Susac’s syndrome. Neurology 2003; 61 (12) 1783-7.
• 53 White ML, Zhang Y, Smoker WR. Evolution of lesions in Susac syndrome at serial MR imaging with diffusion-weighted imaging and apparent diffusion coefficient values. AJNR Am J Neuroradiol 2004; 25 (05) 706-13.
• 54 Kleffner I. et al. Diffusion tensor imaging demonstrates fiber impairment in Susac syndrome. Neurology 2008; 70 (19 Pt 2) 1867-9.
• 55 Egan RA, Hills WL, Susac JO. Gass plaques and fluorescein leakage in Susac Syndrome. J Neurol Sci 2010; 299 (1–2) 97-100.
• 56 Hilgert E, Harrèus U, Kramer MF, Matthias C. [Susac’s syndrome. A rare microangiopathy of cochlea, retina, and brain]. HNO 2006; 54 (04) 303-6.
• 57 Papo T. et al. Susac syndrome. Medicine (Baltimore) 1998; 77 (01) 3-11.
• 58 Pawate S, Agarwal A, Moses H, Sriram S. The spectrum of Susac’s syndrome. Neurol Sci 2009; 30 (01) 59-64.
• 59 Mallam B, Damato EM, Scolding NJ, Bailey C. Serial retinal fluorescein angiography and immune therapy in Susac’s syndrome. J Neurol Sci 2009; 285 (1–2) 230-4.
• 60 Rennebohm RM, Egan RA, Susac JO. Treatment of Susac’s Syndrome. Curr Treat Options Neurol 2008; 10 (01) 67-74.
• 61 Fox RJ. et al. Treatment of Susac syndrome with gamma globulin and corticosteroids. J Neurol Sci 2006; 251 (1–2) 17-22.
• 62 Gean-Marton AD. et al. Abnormal corpus callosum: a sensitive and specific indicator of multiple sclerosis. Radiology 1991; 180 (01) 215-21.
• 63 Paty DW. et al. MRI in the diagnosis of MS: a prospective study with comparison of clinical evaluation, evoked potentials, oligoclonal banding, and CT. Neurology 1988; 38 (02) 180-5.